ArticleDiscover oncology2025
Unraveling the TEC-associated landscape in hepatocellular carcinoma: a comprehensive study based on multi-omics analyses.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor microenvironment (TME) plays a pivotal role in tumor progression, immune evasion, and therapeutic responses. Among its key components, endothelial cells (ECs) are crucial regulators of angiogenesis, immune cell trafficking, and metabolic adaptations. This study integrates single-cell and transcriptomic analyses to identify tumor-specific endothelial cell signatures in hepatocellular carcinoma (HCC) and stratify tumors into three distinct molecular subtypes. These subtypes exhibit unique immune landscapes and biological characteristics, including pathway activation and differential responses to immunotherapy and targeted treatments. Using machine learning, we developed a robust prognostic scoring model to predict patient outcomes and therapy responsiveness, which was validated across independent cohorts. Our findings highlight the critical role of endothelial cells in modulating the TME and underscore the potential of targeting EC-specific molecular features to enhance the efficacy of immunotherapy and optimize personalized cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.